Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Precigen ( (PGEN) ) is now available.
On August 18, 2025, Precigen, Inc. announced that its product PAPZIMEOS received FDA approval as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. This approval positions PAPZIMEOS as a potential standard-of-care treatment, offering a new paradigm for managing RRP, which was previously treated mainly through surgical interventions. The approval is expected to significantly impact Precigen’s market positioning and provide a new therapeutic option for the estimated 27,000 adult RRP patients in the US.
The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.
Spark’s Take on PGEN Stock
According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.
Precigen’s overall stock score is primarily impacted by its weak financial performance, which poses significant risks. However, strong technical momentum and positive corporate events provide some optimism. The valuation remains unattractive due to ongoing losses.
To see Spark’s full report on PGEN stock, click here.
More about Precigen
Precigen, Inc. operates in the biotechnology industry, focusing on developing innovative gene and cell therapies. The company is primarily engaged in creating treatments for complex diseases, with a notable emphasis on immunotherapies and genetic medicines.
Average Trading Volume: 5,164,658
Technical Sentiment Signal: Buy
Current Market Cap: $876M
See more data about PGEN stock on TipRanks’ Stock Analysis page.